Vismodegib: Clinical Trials

19 trials of Vismodegib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 4 terminated, 1 active not recruiting, 1 suspended. 19 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 119Completed 13, Terminated 4, Active not recruiting 1, Suspended 1
Phase 26Completed 4, Terminated 2

Follow Vismodegib: new trials by email Literature Review of Vismodegib trials Research Report on Vismodegib

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Atezolizumab, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Phase 1SuspendedDwight Owen242024-12-312026-09-18
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1TerminatedOHSU Knight Cancer Institute22020-04-012024-03-04
NCT Neuro Master Match - N²M² (NOA-20)
APG101, Alectinib, Idasanutlin - Glioblastoma, Adult
Phase 1 / Phase 2CompletedUniversity Hospital Heidelberg2282018-05-072023-09-28
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Pembrolizumab, Vismodegib - Skin Basal Cell Carcinoma
Phase 1 / Phase 2CompletedAnne Chang162016-02-012019-03-08
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
Placebo, Ruxolitinib, Vismodegib - Myelofibrosis
Phase 1CompletedHoffmann-La Roche102016-01-252018-05-11
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
Pirfenidone, Vismodegib - Idiopathic Pulmonary Fibrosis
Phase 1CompletedHoffmann-La Roche212016-01-152017-10-30
Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
Vismodegib - Basal Cell Carcinoma
Phase 1CompletedUniversity of Arizona42015-11-302018-07-18
A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib
fluconazole, itraconazole, rabeprazole - Healthy Volunteer
Phase 1CompletedGenentech, Inc.922013-02-012016-11-02
Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
vismodegib, Temozolomide - Histologically Confirmed Medulloblastoma, Activation of the Sonic Hedgehog (SHH) Pathway
Phase 1 / Phase 2TerminatedCentre Leon Berard242012-06-012019-05-21
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
vismodegib, sirolimus, positron emission tomography - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Phase 1CompletedMayo Clinic312012-03-052019-04-08
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
Vismodegib - Cancer
Phase 1CompletedGenentech, Inc.312012-03-012016-05-23
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Phase 1CompletedNational Cancer Institute (NCI)502010-12-012014-12-23
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol - Solid Cancers
Phase 1CompletedGenentech, Inc.522010-11-012015-06-29
Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate - Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)102010-07-092019-02-28
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)782010-06-012018-08-15
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study - Estrogen Receptor Negative, HER2/Neu Negative
Phase 1TerminatedNational Cancer Institute (NCI)132009-11-012015-04-15
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Pharmacological Study, Vismodegib - Malignant Neoplasm
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)632009-10-012017-05-19
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Diagnostic Laboratory Biomarker Analysis, Erlotinib Hydrochloride, Gemcitabine Hydrochloride - Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)552009-03-312026-11-18
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
vismodegib, laboratory biomarker analysis, pharmacological study - Recurrent Childhood Medulloblastoma
Phase 1CompletedNational Cancer Institute (NCI)342009-01-012014-04-02

Conditions studied

Pancreatic Neoplasms (3)  ·  Breast Neoplasms (2)  ·  Carcinoma, Basal Cell (2)  ·  Medulloblastoma (2)  ·  Multiple Myeloma (2)  ·  Neoplasms (2)  ·  Primary Myelofibrosis (2)  ·  Prostatic Neoplasms (2)  ·  Anemia (1)  ·  Blast Crisis (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Chondrosarcoma (1)  ·  Chondrosarcoma, Extraskeletal Myxoid (1)  ·  Dermatofibrosarcoma (1)  ·  Desmoplastic Small Round Cell Tumor (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  Genentech, Inc. (3)  ·  Hoffmann-La Roche (2)  ·  Anne Chang (1)  ·  Centre Leon Berard (1)  ·  Dwight Owen (1)  ·  Mayo Clinic (1)  ·  OHSU Knight Cancer Institute (1)  ·  University Hospital Heidelberg (1)  ·  University of Arizona (1)

Countries

United States (17)  ·  Germany (3)  ·  Italy (2)  ·  Canada (1)  ·  France (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Amar Gajjar (1)  ·  Anne Lynn S Chang, MD (1)  ·  Carol Huff (1)  ·  Charles Erlichman (1)  ·  Charles Erlichman, M.D. (1)  ·  Christopher Logothetis (1)  ·  Dawn Colburn, Pharm.D. (1)  ·  Dwight H Owen, MD (1)  ·  Lara Davis, MD (1)  ·  Manish Sharma (1)  ·  Mariette Marsh (1)  ·  Mrinal Gounder (1)  ·  Patricia LoRusso (1)  ·  Wolfgang Wick, Prof. Dr. (1)

Results publications

PMID 20818327, PMID 27154174, PMID 30249277, PMID 32026407, PMID 39863139, PMID 40913172

NIH funding

2015 (3), U01CA070095 (2), N01CM00039 (1), N01CM62202 (1), N01CM62206 (1), P30CA006973 (1), P30CA008748 (1), P30CA014599 (1), P30CA015083 (1), P30CA016672 (1), P30CA022453 (1), P30CA124435 (1), P50CA102701 (1), U01CA062461 (1), U01CA062487 (1)